发明名称 |
Pyrazoloanthrone and derivatives thereof for the treatment of cancers expressing MISRII |
摘要 |
Provided herein are pyrazoloanthrones or functional derivatives or analogs thereof to activate MIS receptor-mediated downstream effects in a cell. In particular, methods are provided to prevent and treat cancer that expresses MIS receptor type II (MISRII) by administering to a subject at least one pyrazoloanthrone or a functional derivative or analog thereof. Also provided herein are methods to lower plasma androgen levels in a subject, and/or for the treatment of a subject with a disease characterized by excess androgen, whereby the subject is administered at least one pyrazoloanthrone or a functional derivative or analog thereof. Also provided are methods to decrease the dose of a chemotherapeutic agent by administering the chemotherapeutic agent with a pyrazoloanthrone or a functional derivative or analog thereof that lowers the effective dose of the chemotherapeutic agent. |
申请公布号 |
US9260759(B2) |
申请公布日期 |
2016.02.16 |
申请号 |
US201113328387 |
申请日期 |
2011.12.16 |
申请人 |
The General Hospital Corporation |
发明人 |
Teixeira Jose;Donahoe Patricia K. |
分类号 |
A61K38/00;A61K31/415;A01N59/00;C12Q1/68 |
主分类号 |
A61K38/00 |
代理机构 |
Nixon Peabody LLP |
代理人 |
Nixon Peabody LLP |
主权项 |
1. A method of decreasing the dose of a chemotherapeutic agent for the treatment of cancer expressing Mullerian Inhibiting Substance Receptor II (MISRII), the method comprising administering to the subject a therapeutically effective amount of a pyrazoloanthrone compound and at least one or a combination of chemotherapeutic agents selected from the group consisting of: paclitaxel, cisplatin, doxorubicin, rapamycin, Mullerian Inhibiting Substance (MIS) or recombinant human MIS (rhMIS), wherein the therapeutically effective dose of the chemotherapeutic agent for an apoptotic effect on a cancer cell expressing MISRII in the presence of the pyrazoloanthrone compound is lower as compared to the therapeutically effective dose of the chemotherapeutic agent for the same apoptotic effect on a cancer cell expressing MISRII in the absence of the pyrazoloanthrone compound. |
地址 |
Boston MA US |